- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00226616
Zinc Supplementation in Cholera Patients
Clinical Trial of Zinc Supplementation in Cholera Patients
Study Overview
Detailed Description
Study design:
A double blind randomized clinical trial using zinc and placebo.
Randomization:
Patients will be randomized to one of two groups, A or B. Block randomization will be done using block length of 6. Group A will receive Zinc+ Erythromycin and Group B: will receive Placebo+Erythromycin
Dose of Erythromycin
Syrup/tab Erythromycin 50mg/kg/24 hours in 4 divided doses for 3 days.
Dose of zinc:
Zinc acetate will be given at 10mg twice daily (10mgx2=20mg elemental zinc) until cholera resolves (the time of passage of last unformed stool or first formed stool followed by 24 hours without any diarrheal stool).
Composition of the syrup:
For both groups, the bulk of the base syrup will be consist of the same chemicals; in addition to this, group A will have the treatment substance (i.e. elemental zinc 20 mg/day)
Syrup A: Quantity per 5 ml
Zinc Acetate 10 mg elemental zinc
Syrup B: Base substance
Base Substance:
Ascorbic acid 30 mg Glycerin USP 1.2 ml Propylene glycol USP 0.75 ml Sorbitol 70% BP 2.0 ml Methyl Paraben USFN 3.5 mg Polysorate-80 50 mg (Tween -80) BPC Lemon oil PH grade 0.0125 ml Caramel Brown colour 1 mg Purified water 0.75 ml
Clinical procedure in the hospital:
Patients who meet the selection criteria will be observed for initial six hours, while their urine and stool specimen will be collected separately. Patient whose initial stool-output >4ml/kg/hour during this period and dark field examination of stool is positive will be enrolled in the study. Patients will be kept in study ward. After complete hydration, patients will be randomised in blocks of 6 to one of two groups A and B. Group A will receive syrup zinc and group B will receive placebo till cholera resolves. Both the groups will receive the identical bottles containing syrup with same flavor and only single unique serial number will be written on the bottles. The number will indicate an exact subject of study. Both the groups will receive Syrup/Tab Erythromycin. 1ml blood will be collected for serum zinc on admission after complete dehydration and this test will be repeated at the time of discharge. Stool culture and sensitivity (C/S) will be sent daily until the day of recovery or 5 days. Balance will be performed on all the patients till cholera resolves. If any complication develops after enrollment, study will be discontinued and patient will be treated accordingly.
Assessment of dehydration:
To reduce observational variation, especially regarding the assessment of dehydration, a standardized form is developed for the assessment of dehydration.
CONDITION* (1=normal, 2=irritable/lessactive, 3=lethargic/comatose) MUCOSA (1=normal, 2=dry)
EYES (1=normal, 2=sunken) THIRST* (1=normal, 2=thirsty, 3=unable to drink) SKIN TURGOR* (1=normal, 2=reduced) PULSE* (1=normal, 3=feeble/absent)
DEHYDRATION STATUS:
- no sign of dehydration
- some dehydration (two signs coded 2 with at least one key sign*)
- severe dehydration (some dehydration, plus one key sign* coded 3)
(* This method was recently validated by a group of international experts in oral rehydration therapy who were invited to ICDDR, B and is currently being used in a large WHO sponsored multi-centre trial for the evaluation of low osmolarity ORS. The investigators have been trained in this method).
Rehydration phase:
All the patients recruited in this study, will have either, some dehydration or severe dehydration. Therefore, before being randomized into study, during initial 6 hours all the patients will be rehydrated either by ORS or intravenous fluid. Patients with signs of some dehydration will be rehydrated by ORS and patients with severe dehydration will be rehydrated intravenously as described below. The following IV fluids will be used:
Sodium Potassium Chloride Acetate Dhaka Solution (mmol/L) (mmol/L) (mmol/L) (mmol/L) 133 13 98 48 Rate of administration will be 100 ml/kg over 4 hours, plus volume-for-volume replacement for ongoing losses hourly.
If, at the end of four hours:
- The patient is fully rehydrated, he/she will be randomized to one of the treatment groups;
- Some dehydration persist, IV infusion will continue at the rate of 50 ml /kg over 2 hours, plus replacement volume for volume of ongoing losses;
- Severe dehydration persists, IV infusion will continue for an additional 2 hours at the rate of 100 ml/kg, plus replacement of ongoing losses. This is very unusual, however, occurring only in very few patients who pass large watery stools frequently.
If at the end of six hours, the patient is fully rehydrated patient will be randomized to one of the treatment group. If signs of dehydration persist after 6 hours, the patient will be excluded from study. All intake and output during this initial rehydration phase will be recorded.
Maintenance phase:
After completion of rehydration, subjects will be randomized to one of the two groups Group A and Group B. Group A will be given zinc acetate and group B will be given placebo. The supplementation of zinc or placebo will be continued till diarrhea resolves. Ongoing stool losses will be replaced with equal volume of Rice-ORS.
Dietary management:
Standardize hospital diet will be given to all patients which includes milk suji, rice, vegetable, daal, bread banana and chicken or fish.
Intake and output measurement:
All oral and intravenous fluid will be measured and recorded until cholera resolves. Stool weight will be measured separately from urine every 8 hours until cholera resolves. Urine will be separated and measured 8 hourly, weight of vomitus will also be taken 8 hourly. Daily clinical examination will be done by the investigators and study physician with observation on stool consistency and character.
Clinical recovery:
Clinical recovery will be defined as the time of passage of last unformed stool or first formed stool followed by 24 hours without any diarrheal stool.
Sample size calculation:
We assume that zinc will reduce 20% of mean duration of illness compared to erythromycin group18 at 90% power and 5% level of confidence. Therefore the sample size will be:
n=2 (SD)2 aß/(D)2 n=2 (5)2 10.5/(2.6)2 n=77.66=78 per treatment group So the total number of samples will be 78 x 2 =156. Considering 15% drop out the total number of samples will be 156+24=180
Assessment of weight gain:
Weight will be taken on admission and daily until cholera resolves.
Laboratory tests:
Microscopic examination
1. Dark field examination will be done on stool samples on admission.
Microbiological assays:
1 Daily stool C/S will be done till cholera resolves or 5 days.
Micronutrient assay:
- Serum zinc level will be obtained on day 1 and on the day of recovery
- Randomly zinc loss in cholera will be seen in 20% samples.
Study Type
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Dhaka, Bangladesh, 1000
- ICDDR,B, Dhaka hospital
-
Dhaka, Bangladesh, 1000
- S.k.Roy
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Children aged between 3-14 years hospitalized at ICDDR, B presenting with cholera within 24 hours of onset.
- Stool output more than 4ml/kg/hour within the first 6 hours of observation period.
- Positive dark field examination
Exclusion Criteria:
- Unable to rehydrate within 6 hours
- Negative dark field examination
- Systemic illness requiring immediate administration of antibiotics.
- Received antibiotics in the 24 hours prior to hospitalization
- Patients presenting with bloody mucoid diarrhea
- Unconscious or medical emergencies
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Reduction in duration of diarrhoea
|
Reeudction in total stool volume
|
Secondary Outcome Measures
Outcome Measure |
---|
Serum Zinc status
|
Collaborators and Investigators
Investigators
- Principal Investigator: Swapan K Roy, MBBS,MSc,Phd, International Centre for Diarrhoeal Disease Research, Bangladesh
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 99-022
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cholera
-
Johns Hopkins Bloomberg School of Public HealthBill and Melinda Gates Foundation; Meilleur Accès aux Soins de Santé (M.A....CompletedCholera Vaccination Reaction | Adverse Reaction to Cholera VaccineCameroon
-
Brigham and Women's HospitalRecruitingCholera | Cholera Vaccine ToxicityUnited States
-
Bavarian NordicEmergent BioSolutionsCompleted
-
International Vaccine InstituteMassachusetts General Hospital; EuBiologics Co.,LtdRecruitingCholera Vaccination ReactionKorea, Republic of
-
Jiangsu Province Centers for Disease Control and...CompletedSafety of the Oral O1 / O139 Cholera Vaccine (Enteric Capsules)
-
University of Maryland, BaltimoreRecruitingTyphoid and/or Cholera VaccinationUnited States
-
Bharat Biotech International LimitedRecruiting
-
Bavarian NordicEmergent BioSolutionsCompletedCholeraUnited States, Australia
-
National Institute of Allergy and Infectious Diseases...Completed
Clinical Trials on Zinc
-
International Centre for Diarrhoeal Disease Research...Completed
-
Hormozgan University of Medical SciencesCompleted
-
Lesaffre InternationalCompleted
-
National University Hospital, SingaporeNational University, SingaporeCompletedDiabetes Mellitus, Non-Insulin-Dependent
-
Instituto Nacional de Salud Publica, MexicoUNICEFCompletedDiarrhea, Infantile | Diarrhoea;AcuteMexico
-
Tufts UniversityBoston University; Boston Medical Center; Hebrew SeniorLifeCompletedDisorder of Immune Function
-
University of California, DavisBill and Melinda Gates Foundation; Helen Keller International; Université Polytechnique...Completed
-
University of UtahIntermountain Research and Medical FoundationTerminatedBronchopulmonary Dysplasia | Growth Failure | Infant,PrematureUnited States
-
CES UniversityNutreva S.A.S.; Foundation Child Care - FANCompleted
-
UCSF Benioff Children's Hospital OaklandChildren's Hospital of Philadelphia; National Heart, Lung, and Blood Institute... and other collaboratorsCompleted